Low-dose Ketamine treatment is a breakthrough, effective, and accessible option for millions of people struggling with depression and anxiety.
We've treated over 50,000 patients with extraordinary results, including for patients with treatment-resistant depression.
Ketamine is believed to affect neuroplasticity and mood regulation through its modulation of glutamate and its interactions with NMDA receptors. By blocking NMDA receptors, ketamine disrupts normal glutamate neurotransmission, supporting synaptic plasticity and contributing to the antidepressant effects found with ketamine treatment. Patients are able to make new neural connections and gain new perspectives over old triggers, beliefs, and experiences.
Ketamine is also believed to stimulate synaptogenesis by increasing BDNF (brain-derived neurotrophic factor) levels in certain brain regions. Depression and chronic stress can cause synaptic dysfunction by reducing the number of neuronal synapses in brain regions that regulate mood and cognition. Ketamine has been shown to promote the growth of new synapses, called synaptogenesis, contributing to the long-term antidepressant potential of ketamine treatment.